ES2912099T3 - Composiciones para prevenir y/o tratar una infección por un virus VIH-1 - Google Patents

Composiciones para prevenir y/o tratar una infección por un virus VIH-1 Download PDF

Info

Publication number
ES2912099T3
ES2912099T3 ES12718402T ES12718402T ES2912099T3 ES 2912099 T3 ES2912099 T3 ES 2912099T3 ES 12718402 T ES12718402 T ES 12718402T ES 12718402 T ES12718402 T ES 12718402T ES 2912099 T3 ES2912099 T3 ES 2912099T3
Authority
ES
Spain
Prior art keywords
peptide
hiv
formula
cells
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12718402T
Other languages
English (en)
Spanish (es)
Inventor
Patrice Debre
Vincent Vieillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Minka Therapeutics
Institut National de la Santé et de la Recherche Médicale
Original Assignee
Minka Therapeutics
Institut National de la Santé et de la Recherche Médicale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minka Therapeutics, Institut National de la Santé et de la Recherche Médicale filed Critical Minka Therapeutics
Application granted granted Critical
Publication of ES2912099T3 publication Critical patent/ES2912099T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
ES12718402T 2011-04-15 2012-04-13 Composiciones para prevenir y/o tratar una infección por un virus VIH-1 Active ES2912099T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11305451A EP2511295A1 (en) 2011-04-15 2011-04-15 Compositions for preventing and/or treating an infection by an HIV-1 virus
PCT/IB2012/051842 WO2012140620A1 (en) 2011-04-15 2012-04-13 Compositions for preventing and/or treating an infection by an hiv-1 virus

Publications (1)

Publication Number Publication Date
ES2912099T3 true ES2912099T3 (es) 2022-05-24

Family

ID=44721142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12718402T Active ES2912099T3 (es) 2011-04-15 2012-04-13 Composiciones para prevenir y/o tratar una infección por un virus VIH-1

Country Status (11)

Country Link
US (3) US9181299B2 (cg-RX-API-DMAC10.html)
EP (2) EP2511295A1 (cg-RX-API-DMAC10.html)
JP (1) JP6027094B2 (cg-RX-API-DMAC10.html)
CN (1) CN103687875B (cg-RX-API-DMAC10.html)
BR (1) BR112013026150B1 (cg-RX-API-DMAC10.html)
CA (1) CA2831258C (cg-RX-API-DMAC10.html)
ES (1) ES2912099T3 (cg-RX-API-DMAC10.html)
RU (1) RU2603262C2 (cg-RX-API-DMAC10.html)
UA (1) UA112863C2 (cg-RX-API-DMAC10.html)
WO (1) WO2012140620A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201307019B (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016184962A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
BR112019021787A2 (pt) * 2017-04-18 2020-05-05 Inst Pathogen Biology Cams lipopeptídeo para inibição potente do hiv, seu derivado, composição farmacêutica e uso do mesmo
EP4115900A1 (en) * 2021-07-05 2023-01-11 Diaccurate Novel antigens and vaccines

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
WO2000061761A2 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
US6436703B1 (en) * 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
US6399067B1 (en) * 2000-04-28 2002-06-04 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
AU2002251058A1 (en) * 2001-02-16 2002-09-04 Hybrigenics Protein-protein interactions in saccharomyces cerevisiae
FR2851165A1 (fr) * 2003-02-19 2004-08-20 Aventis Pasteur Antigene derivant de l'helice c de la proteine gp41
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2009026353A1 (en) * 2007-08-20 2009-02-26 New York University Immunogen presenting hiv gp120 v3 loop in a conformation that induces broadly neutralizing antibodies
CN104232679A (zh) * 2009-01-28 2014-12-24 巴斯夫植物科学有限公司 具有增强的产量相关性状的植物及其制备方法
AP3402A (en) * 2009-02-06 2015-08-31 Mymetics Corp Splitting GP41
WO2011005289A2 (en) * 2009-06-23 2011-01-13 President And Fellows Of Harvard College Methods and kits for measuring enzyme activity

Also Published As

Publication number Publication date
US9181299B2 (en) 2015-11-10
WO2012140620A1 (en) 2012-10-18
US9802983B2 (en) 2017-10-31
WO2012140620A8 (en) 2013-11-07
CN103687875B (zh) 2016-10-19
RU2603262C2 (ru) 2016-11-27
ZA201307019B (en) 2014-12-23
JP6027094B2 (ja) 2016-11-16
BR112013026150A2 (pt) 2016-09-06
EP2697259A1 (en) 2014-02-19
US20180057535A1 (en) 2018-03-01
EP2511295A1 (en) 2012-10-17
EP2697259B1 (en) 2022-02-09
CA2831258A1 (en) 2012-10-18
JP2014512367A (ja) 2014-05-22
US20140037666A1 (en) 2014-02-06
US20160031943A1 (en) 2016-02-04
CN103687875A (zh) 2014-03-26
US10174080B2 (en) 2019-01-08
UA112863C2 (uk) 2016-11-10
CA2831258C (en) 2020-07-14
BR112013026150B1 (pt) 2022-08-09
RU2013145467A (ru) 2015-05-20

Similar Documents

Publication Publication Date Title
KR100547049B1 (ko) 바이러스 감염증 치료를 위한 조성물 및 방법
JP2022174144A (ja) チクングニヤウイルスの抗体媒介性中和
WO2012045001A2 (en) Influenza virus antibodies and immunogens and uses therefor
PT90376B (pt) Processo para a preparacao de peptidos env-codificados de hiv capazes de elicitarem anticorpos que inibem hiv em mamiferos e de anticorpos monoclonais que inibem hiv mediante utilizacao desses peptidos
CN101646691B (zh) 作为HIVgp120抗原的模拟表位的抗独特型单克隆抗体
WO2022216223A1 (en) Vaccine and/or antibody for viral infection
US10174080B2 (en) Compositions for preventing and/or treating an infection by an HIV-1 virus
WO2016184963A1 (en) Treatment of hiv-infected individuals
US11851478B2 (en) Antibody-mediated neutralization of chikungunya virus
WO2016184962A1 (en) Treatment of hiv-infected individuals
WO2016184973A1 (en) Treatment of hiv-infected individuals
CN109627297A (zh) 来自寨卡病毒e蛋白的中和表位及其应用
AU2017251715A1 (en) Antibody recognizing arbitrarily designed epitope of three or more amino acid residues in a peptide and method of generating thereof
JP2008535783A (ja) Ｈｉｖ−１の増殖を弱めるための方法および組成物
Kim et al. Enhancing HIV-1 neutralization by increasing the local concentration of MPER-directed bnAbs
US10273292B2 (en) Non-HIV vaccine antigen from the vaginal microbiota capable of inducing a mucosal neutralizing protective antibody response against HIV infection
CN105980405A (zh) Hiv抗原和抗体及其组合物、方法和用途
WO2023039064A2 (en) Broadly neutralizing antibodies against sars-like viruses
JP2022541900A (ja) Ｈｉｖ結合剤
HK1236038A1 (en) Treatment and functional cure of hiv infection by monoclonal antibodies to cd4 mediating competitive hiv entry inhibition